Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1963 3
1964 2
1965 4
1966 1
1967 2
1968 2
1969 2
1970 5
1971 8
1972 7
1973 1
1974 5
1975 4
1976 5
1977 6
1978 1
1979 5
1980 3
1981 1
1982 5
1983 6
1984 2
1985 5
1986 3
1987 6
1988 10
1989 10
1990 4
1991 10
1992 14
1993 34
1994 24
1995 22
1996 22
1997 28
1998 18
1999 20
2000 26
2001 24
2002 27
2003 16
2004 22
2005 23
2006 28
2007 24
2008 23
2009 25
2010 29
2011 28
2012 31
2013 35
2014 24
2015 20
2016 29
2017 26
2018 27
2019 37
2020 32
2021 36
2022 32
2023 18

Text availability

Article attribute

Article type

Publication date

Search Results

906 results

Results by year

Filters applied: . Clear all
Page 1
Myotonic dystrophy.
Thornton CA. Thornton CA. Neurol Clin. 2014 Aug;32(3):705-19, viii. doi: 10.1016/j.ncl.2014.04.011. Epub 2014 Jun 6. Neurol Clin. 2014. PMID: 25037086 Free PMC article. Review.
Myotonic dystrophy (dystrophia myotonica, DM) is one of the most common lethal monogenic disorders in populations of European descent. ...More recently, a second form of the disease, DM type 2 was recognized, which results from repeat expansion in a different gene. …
Myotonic dystrophy (dystrophia myotonica, DM) is one of the most common lethal monogenic disorders in populations of European …
Myotonic Dystrophy.
Hamel JI. Hamel JI. Continuum (Minneap Minn). 2022 Dec 1;28(6):1715-1734. doi: 10.1212/CON.0000000000001184. Continuum (Minneap Minn). 2022. PMID: 36537977 Review.
PURPOSE OF REVIEW: Myotonic dystrophy type 1 (DM1) and myotonic dystrophy type 2 (DM2) are genetic disorders affecting skeletal and smooth muscle, heart, brain, eyes, and other organs. ...RECENT FINDINGS: Studies of the multisystem involvement of myotonic …
PURPOSE OF REVIEW: Myotonic dystrophy type 1 (DM1) and myotonic dystrophy type 2 (DM2) are genetic disorders affecting …
Guidelines on clinical presentation and management of nondystrophic myotonias.
Stunnenberg BC, LoRusso S, Arnold WD, Barohn RJ, Cannon SC, Fontaine B, Griggs RC, Hanna MG, Matthews E, Meola G, Sansone VA, Trivedi JR, van Engelen BGM, Vicart S, Statland JM. Stunnenberg BC, et al. Muscle Nerve. 2020 Oct;62(4):430-444. doi: 10.1002/mus.26887. Epub 2020 May 27. Muscle Nerve. 2020. PMID: 32270509 Free PMC article. Review.
The nondystrophic myotonias are rare muscle hyperexcitability disorders caused by gain-of-function mutations in the SCN4A gene or loss-of-function mutations in the CLCN1 gene. ...In the absence of genetic confirmation, the diagnosis is supported by detailed electrophysiolo …
The nondystrophic myotonias are rare muscle hyperexcitability disorders caused by gain-of-function mutations in the SCN4A gene or los …
Myotonic dystrophy type 2: the 2020 update.
Meola G. Meola G. Acta Myol. 2020 Dec 1;39(4):222-234. doi: 10.36185/2532-1900-026. eCollection 2020 Dec. Acta Myol. 2020. PMID: 33458578 Free PMC article. Review.
Despite clinical and genetic similarities, myotonic dystrophy type 1 and type 2 are distinct disorders requiring different diagnostic and management strategies. Gene therapy for myotonic dystrophy type 1 and myotonic dystrophy type 2 appears to be very …
Despite clinical and genetic similarities, myotonic dystrophy type 1 and type 2 are distinct disorders requiring different dia …
Myotonic dystrophy: diagnosis, management and new therapies.
Turner C, Hilton-Jones D. Turner C, et al. Curr Opin Neurol. 2014 Oct;27(5):599-606. doi: 10.1097/WCO.0000000000000128. Curr Opin Neurol. 2014. PMID: 25121518 Review.
PURPOSE OF REVIEW: Myotonic dystrophies type 1 and type 2 are progressive multisystem genetic disorders with clinical and genetic features in common. ...The average age of death in myotonic dystrophy type 1 is in the fifth decade. In comparison, myotonic …
PURPOSE OF REVIEW: Myotonic dystrophies type 1 and type 2 are progressive multisystem genetic disorders with clinical and gene …
Myotonic dystrophy type 1 drug development: A pipeline toward the market.
Pascual-Gilabert M, López-Castel A, Artero R. Pascual-Gilabert M, et al. Drug Discov Today. 2021 Jul;26(7):1765-1772. doi: 10.1016/j.drudis.2021.03.024. Epub 2021 Mar 31. Drug Discov Today. 2021. PMID: 33798646 Free PMC article. Review.
Myotonic dystrophy type 1 (DM1) is a multisystemic neuromuscular genetic disease with an estimated prevalence of approximately at least half a million individuals based on its vast ethnic variation. ...
Myotonic dystrophy type 1 (DM1) is a multisystemic neuromuscular genetic disease with an estimated prevalence of approximately at lea …
Muscle channelopathies.
Vivekanandam V, Jayaseelan D, Hanna MG. Vivekanandam V, et al. Handb Clin Neurol. 2023;195:521-532. doi: 10.1016/B978-0-323-98818-6.00006-6. Handb Clin Neurol. 2023. PMID: 37562884 Review.
Muscle channelopathies encompass a wide range of mainly episodic conditions that are characterized by muscle stiffness and weakness. The myotonic conditions, characterized predominantly by stiffness, include myotonia congenita, paramyotonia congenita, …
Muscle channelopathies encompass a wide range of mainly episodic conditions that are characterized by muscle stiffness and weakness. The …
The myotonic dystrophy type 1 drug development pipeline: 2022 edition.
Pascual-Gilabert M, Artero R, López-Castel A. Pascual-Gilabert M, et al. Drug Discov Today. 2023 Mar;28(3):103489. doi: 10.1016/j.drudis.2023.103489. Epub 2023 Jan 9. Drug Discov Today. 2023. PMID: 36634841 Free article. Review.
The beginning of the 20th decade has witnessed an increase in drug development programs for myotonic dystrophy type 1 (DM1). We have collected nearly 20 candidate drugs with accomplished preclinical and clinical phases, updating our previous drug development pipeline revie …
The beginning of the 20th decade has witnessed an increase in drug development programs for myotonic dystrophy type 1 (DM1). We have …
Strength training and aerobic exercise training for muscle disease.
Voet NB, van der Kooi EL, Riphagen II, Lindeman E, van Engelen BG, Geurts AC. Voet NB, et al. Cochrane Database Syst Rev. 2013 Jul 9;(7):CD003907. doi: 10.1002/14651858.CD003907.pub4. Cochrane Database Syst Rev. 2013. PMID: 23835682 Free article. Updated. Review.
AUTHORS' CONCLUSIONS: Moderate-intensity strength training in myotonic dystrophy and FSHD and aerobic exercise training in dermatomyositis and polymyositis and myotonic dystrophy type I appear to do no harm, but there is insufficient evidence to conclude that they o …
AUTHORS' CONCLUSIONS: Moderate-intensity strength training in myotonic dystrophy and FSHD and aerobic exercise training in dermatomyo …
Muscle Channelopathies.
Trivedi JR. Trivedi JR. Continuum (Minneap Minn). 2022 Dec 1;28(6):1778-1799. doi: 10.1212/CON.0000000000001183. Continuum (Minneap Minn). 2022. PMID: 36537980 Review.
Randomized clinical trials have now been conducted in these disorders with expanded treatment options for patients with muscle channelopathies. ...
Randomized clinical trials have now been conducted in these disorders with expanded treatment options for patients with muscle channe …
906 results